NEW YORK (GenomeWeb News) – Cepheid said this week that it released an improved Xpert BCR-ABL Monitor test as a CE IVD product in the European Union. The firm said that the new test, which is used to monitor patients with chronic myelogenous leukemia, detects BCR-ABL chromosomal translocation in about 2 hours as compared to 2.5 hours for the original product release.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.